Do CLDN2 and PRSS1/PRSS2 variants increase risk of chronic pancreatitis and subsequent exocrine pancreatic insufficiency?

Chronic pancreatitis (CP) is a progressive inflammatory disease characterized by irreversible structural damage to the pancreas, frequently leading to profound functional impairment. Extensive genomic and clinical research confirms that specific genetic markers increase susceptibility to this condition and that its progression is a primary driver of digestive failure.

Clinical and genetic evidence

Research involving large-scale genome-wide association studies (GWAS) has identified the PRSS1-PRSS2 locus and the CLDN2 gene as critical determinants of CP risk.

• PRSS1-PRSS2 Locus: Variants at this locus on chromosome 7, such as the rs10273639 haplotype, are strongly associated with CP susceptibility. These variants often lead to gain-of-function effects that increase the risk of premature trypsinogen activation within the pancreas.
• CLDN2 Locus: Variants in the CLDN2 gene on the X chromosome (e.g., rs7057398) significantly increase risk, particularly when combined with environmental factors like alcohol consumption.
• Disease Progression: Clinical data shows that 30–50% of patients with CP will eventually develop exocrine pancreatic insufficiency (EPI). Longitudinal studies indicate that the risk of EPI increases with disease duration, sometimes reaching rates as high as 47% in long-term cohorts.

Mechanistic explanations

The transition from genetic predisposition to clinical pancreatic insufficiency involves distinct molecular and cellular pathways:

• Protease Dysregulation: PRSS1 encodes cationic trypsinogen. Mutations disrupt the balance of protease activity, either by increasing trypsinogen expression or preventing its autolysis (deactivation). This leads to intrapancreatic autodigestion, triggering a cycle of necrosis and inflammation.
• Barrier Dysfunction: CLDN2 encodes claudin-2, a protein regulating tight junctions. Variants disrupt the ductal barrier and paracellular ion transport, creating an environment that favors chronic inflammation and fibrogenesis.
• Acinar Destruction: Chronic inflammation activates pancreatic stellate cells, which deposit excessive collagen, leading to widespread fibrosis. This process replaces functional acinar cells—the primary producers of digestive enzymes—with scar tissue.
• Threshold for Insufficiency: Clinical EPI typically manifests only after approximately 90% of the functional acinar cell mass has been lost, at which point the pancreas can no longer secrete sufficient lipase, amylase, and proteases to maintain normal nutrient absorption.

Bottom line

The association between CLDN2 and PRSS1/PRSS2 variants and chronic pancreatitis is well-supported by high-quality genomic evidence. Furthermore, chronic pancreatitis is a definitive cause of exocrine pancreatic insufficiency, occurring once inflammatory-driven fibrosis destroys approximately 90% of the acinar enzyme-producing capacity.